Compass Posts Trial Data for Psychedelic Drug (CMPS:NASDAQ)

Compass says depression drug has long-lasting benefits

Today's biotech news includes Vertex's largest-ever deal, skyrocketing health insurance costs, and Compass' psilocybin treatment

Compass posts trial data for psychedelic drug (CMPS:NASDAQ)

Compass Pathways (CMPS) stock rises as the company posts new late-stage trial data for its psychedelic therapy COMP360 against depression. Read more here.

Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

LONDON & NEW YORK--(BUSINESS WIRE)--Jul 7, 2026-

Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing

Compass Pathways said Tuesday that patients in the second of its two pivotal psilocybin trials maintained their response to treatment for at least six months, keeping the company on track to complete its NDA filing ...

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch

This morning, Compass Pathways shared 26-week data from its second Phase 3 study of COMP360 psilocybin for treatment-resistant depression (TRD). The data are from Part B of COMP006, the company’s larger (n=581) Phase 3 trial that initially assessed two doses of either 1 mg, 10 mg, or 25 mg of psilocybin 3 weeks apart. The primary endpoint was met, Compass shared in February, when it reported a… Source